To evaluate the effect of netarsudil (AR-13324) ophthalmic solution on aqueous humor dynamics relative to its placebo.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
10
Topical ophthalmic solution
Ophthalmic solution once a day
Aerie Pharmaceutical
Bedminster, New Jersey, United States
Change in aqueous humor flow rate measured by non-contact fluorophotometer
Aqueous humor flow rate measured by non-contact fluorophotometer; change from baseline
Time frame: Day 1 compared to Day 8
Change in outflow facility measured non-invasively by tonography
Outflow facility measured non-invasively by tonography; change from baseline
Time frame: Day 1 compared to Day 8
Change in episcleral venous pressure measured non-invasively by slit-lamp exam
Episcleral venous pressure measured non-invasively by slit-lamp exam; change from baseline
Time frame: Day 1 compared toDay 8
Change in visual acuity measured using eye chart
Visual acuity measured using eye chart; change from baseline
Time frame: Day 1 compared to Day 8
Change in biomicroscopy exam using non-invasive slit-lamp to evaluate cornea, conjunctiva, and anterior chamber of eye
Biomicroscopy exam using non-invasive slit-lamp to evaluate cornea, conjunctiva, and anterior chamber of eye; change from baseline
Time frame: Day 1 compared to Day 8
Safety - Number of participants with adverse events
Number of participants with adverse events as a measure of safety and tolerability
Time frame: Day 1 compared to Day 8
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.